There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PCSK9


PCSK9 Molecule Information

Name:Proprotein convertase subtilisin kexin type 9
Target Synonym:Neural apoptosis-regulated convertase 1;Proprotein convertase 9;Proprotein convertase subtilisin/kexin type 9;NARC1;Subtilisin/kexin-like protease PC9;NARC-1;PCSK9;PC9
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:24
Lastest Research Phase:Approved

PCSK9 Protein Product ListCompare or Buy

PCSK9 Molecule Synonym Name


PCSK9 Molecule Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9), is an enzyme which in humans is encoded by the PCSK9 gene.This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).

PCSK9 References

PCSK9 Related Molecule

PCSK9 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Evolocumab AMG-145 Approved Amgen, Astellas Evolocumab ema Amgen Europe B.V. 2015-07-17 Stroke, Hyperlipoproteinaemia type IIa, Myocardial infarction (MI), Hypercholesterolemia, Familial hypercholesterolemia, Coronary heart disease Details
Alirocumab 316P; REGN-727; SAR-236553  Approved Sanofi, Regeneron Pharmaceutical PRALUENT fda Hypercholesterolemia SANOFI AVENTIS 2015-07-24 Hypercholesterolemia Details

PCSK9 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AK-102 AK-102,AK102 Phase Ⅱ Akeso Biopharma, Yabao Pharmaceutical, Kangrong Oriental (Guangdong) Pharmaceutical Hyperlipidemia Details
K-312 K-312,K312 Phase Ⅰ Kowa Dyslipidemia Details
ALN-PCS ALN-PCS; ALN-PCS01; ALN-PCS02 Phase Ⅰ Almac Discovery, The Medicines Company Hypercholesterolemia Details
SHR-1209 SHR-1209 Phase Ⅱ Jiangsu Hengrui Medicine Hyperlipidemia, Hypercholesterolemia Details
ATH-06 ATH-06; AT-06-A Phase Ⅰ AFFiRiS Atherosclerosis Details
Anti-PCSK9 monoclonal antibody (Biocad) Phase Ⅰ Biocad Cardiovascular disorders Details
SPC-5001 SPC-5001,SPC5001 Phase Ⅰ Roche Familial hypercholesterolemia Details
BMS-844421 BMS 844421; BMSPCSK9Rx; BMS-PCSK9; ISIS-405879 Phase Ⅰ Ionis Pharmaceuticals, Bristol-Myers Squibb Hypercholesterolemia Details
Bococizumab PF-04950615; PF-4950615; RN-316 Phase Ⅲ Pfizer Cardiovascular disorders, Hypercholesterolemia Details
CiVi-007 CiVi-007; LNA-PCSK -9; LNA-PCSK9-GalNac Phase Ⅱ Roche, CiVi Biopharma Hypercholesterolemia Details
SAL-092 SAL092; SAL-092 Phase Ⅰ Salubris Mixed dyslipidemia, Hypercholesterolemia Details
MEDI-4166 MEDI-4166,MEDI4166 Phase Ⅱ MedImmune Cardiovascular disorders, Type 2 diabetes Details
DS-9001 DS-9001 Phase Ⅰ Daiichi Sankyo, Pieris Pharmaceuticals Dyslipidemia Details
Inclisiran ALN-60212; ALN-PCSsc; PCSK9si Phase Ⅲ Alnylam, The Medicines Company Hypercholesterolemia Details
ATH-04 ATH-04 Phase Ⅰ AFFiRiS Atherosclerosis Details
Ralpancizumab PF-05335810; RN 317; PF-5335810 Phase Ⅰ Pfizer Hypercholesterolemia Details
Lodelcizumab LGT-209; NVP-LGT-209 Phase Ⅱ Novartis Hypercholesterolemia Details
CVI-LM001 C-8304; CVI-LM001 Phase Ⅰ CVI Pharmaceuticals Hyperlipidemia Details
Frovocimab LY-3015014 Phase Ⅱ Lilly Hypercholesterolemia Details
LIB-003 LIB-003 Phase Ⅱ LIB Therapeutics Hypercholesterolemia Details
JS-002 JS-002,JS002 Phase Ⅰ Shanghai Junshi Biosciences Hypercholesterolemia Details
BMS-962476 BMS-962476 Phase Ⅰ Bristol-Myers Squibb Hypercholesterolemia Details
IBI-306 IBI-306 Phase Ⅲ Innovent Biologics Hypercholesterolemia Details
RG-7652 RG-7652 Phase Ⅱ Genentech Coronary artery disease (CAD), Metabolic disorders, Hyperlipidemia Details
Recombinant human anti-PCSK9 monoclonal antibody (Salubris) Phase Ⅰ Salubris Mixed dyslipidemia, Hypercholesterolemia Details

This web search service is supported by Google Inc.